

Curriculum Vitae

November 15, 2007

J. DOUGLAS NEWMAN, MD, FRCP[©]

Clinical Investigator

<i>Sun City/Peoria Office (Main Office):</i> PIVOTAL RESEARCH CENTERS 13128 North 94th Drive - Suite 200 Peoria, Arizona 85381 (623) 815-9714 Fax: (623) 815-9759	<i>Mesa Office:</i> PIVOTAL RESEARCH CENTERS 1220 South Alma School Road - Suite 206 Mesa, AZ 85210 (480) 615-3200 Fax: (480) 615-4860
--	---

EDUCATION:

- 1966 – 1967 Toronto Western Hospital, Toronto, Ontario, Canada
Chief Resident in Neurology
FRCP[©]
- 1964 – 1966 Henry Ford Hospital, Detroit, MI
Neurology Resident
- 1962 – 1964 Baylor University College of Medicine, Houston, TX
Neurology Resident
- 1960 – 1962 Hamilton General Hospital, Hamilton, Ontario, Canada
Rotating Internship and Residency in Internal Medicine
- 1954 – 1960 Queen's University, Kingston, Ontario, Canada
Graduated: Ontario, Canada
- 1960 M.D.

PROFESSIONAL EXPERIENCE:

- 11/16/07-Present Pivotal Research Centers, Peoria, Arizona
Pivotal Research Centers, Mesa Arizona (As needed in an emergency)
Clinical Investigator
- 1998 – Present Arizona Neurological Institute, Sun City, AZ
Private Practice in Neurology
- 1997 – 1998 Valley Diagnostic Clinic, Harlingen, TX
Neurology Department
- 1983 – 1997 St. Catherine's, Ontario, Canada
Private Practice in Neurology
- 1978 – 1983 Private Practice in Neurology – Dallas, TX
- 1973 – 1978 St. Catherine's, Ontario, Canada
Private Practice in Neurology

J. Douglas Newman, MD, FRCP[®]
Curriculum Vitae
Page 2 of 6

PROFESSIONAL EXPERIENCE (Continued):

- 1968 – 1973 Henry Ford Hospital, Detroit, MI
 Staff, Neurology Department
- 1967 – 1968 Hospital for Sick Children, Toronto, Ontario, Canada
 Research Fellow in Pediatric Neurology
 Visual Evoked Potentials in Premature Newborn

LICENSURE:

- 1988 Arizona License No. 17328
 DEA Number: BN5232183

BOARD CERTIFICATION:

- 1967 Royal College of Physicians and Surgeons of Canada
 FRCP[®] - Neurology – Certification No. 134

HOSPITAL AFFILIATIONS:

Boswell Memorial Hospital, Sun City, AZ
Del E. Webb Memorial Hospital, Sun City West, AZ
Arrowhead Hospital, Glendale, AZ
Banner Thunderbird Hospital, Glendale, AZ
Banner Estrella Hospital, Phoenix, AZ
West Valley Memorial Hospital, Glendale, AZ
John C. Lincoln Deer Valley Hospital, Phoenix, AZ

PROFESSIONAL MEMBERSHIPS AND SOCIETIES:

- 1967 – Present American Academy of Neurology
1967 – Present Royal College of Physicians and Surgeons of Canada
1967 – Present Ontario College of Physicians and Surgeons
1967 – Present Ontario Medical Association

SPONSORED RESEARCH: [2005 – 2007- Prior to Pivotal Research Centers]

Open-label Multi-Center Trial to Evaluate the Efficacy of Axert 12.5 mg Intervention at Onset of Migraine Pain

Randomized, Parallel-group, Comparison of Treatment with Pharmacotherapy or Adjunctive Vagus Nerve Stimulation Therapy for Pharmacoresistant Partial Seizures: A Large Simple Effectiveness Trial.

Randomized, Parallel-group, Comparison of Treatment with Pharmacotherapy or Adjunctive Vagus Nerve Stimulation Therapy for Pharmacoresistant Partial Seizures in Patients who were not Candidates for Resective Epilepsy Surgery: A Large Simple Effectiveness Trial.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of XXX in Subjects with Mild to Moderate Alzheimer's Disease.

A 24 Week Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Safety, Tolerability and Efficacy Study of the Human Anti-IL-12 Antibody XXX in Subjects with Multiple Sclerosis with a 24-Week Double-Blind Active Extension Phase.

Case Controlled DNA/RNA/SERUM/PLASMA/URINE Banking Study in Caucasians with Multiple Sclerosis.

An Open-Label, Randomized, Crossover Trial to assess Subject Preference for XXX compared to Conventional Baclofen Tablets in Subjects with Stable Multiple Sclerosis.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of a Single, 1-Hour infusion of XXX in Acute Ischemic Stroke (AIS) Patients.

A Randomized, Double-Blind, Controlled Study of XXX for the Treatment of Post-Herpetic Neuralgia.

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, 36-week trial to assess the Efficacy and Safety of adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control with reduced Corticosteroids in Subjects with Myasthenia Gravis.

The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects with mild to moderate Alzheimer's Disease.

A Multi-Center, Double-Blind, Randomized, Parallel Group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in subjects with Partial Seizures.

A 2 year Phase IIIb Randomized, Double-Blind, Multi-Center, Sinemet-controlled, Parallel-Group, Flexible dose study, to assess the Effectiveness of Controlled Release XXX add-on therapy to L-dopa at increasing the time to onset of Dyskinesia in Parkinson's Disease Subjects.

A 12 Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to assess the Efficacy and Safety of XXX (Extended Release Tablets) in Patients with Restless Leg Syndrome.

SPONSORED RESEARCH (Continued): [2005 – 2007- Prior to Pivotal Research Centers]

A Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group study to investigate the Effects of XXX (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in subjects with mild to moderate Alzheimer's Disease.

An Open-Label, Double Conversion Study in Characterize the Pharmacokinetics of LAMOTRIGINE when switching patients with Epilepsy on LAMICTAL Immediate-release to Extended-release and Vice Versa.

A Phase III, 12-Week, Multi-Center, Double-Blind, Double-Dummy, Randomized, Placebo-and Active Comparator-Controlled, Parallel-Group Study to investigate the Efficacy and Safety of XXX 1 mg, 5 mg, 10 mg, 25 mg and 50 mg administered orally, once daily in Adults with Osteoarthritis of the knee.

A Double-Blind, Randomized, Parallel, Efficacy evaluating XXX alone or in Combination with XXX Versus Placebo in Obese Patients with Elevated Systolic and Diastolic Blood Pressure.

Multi-Center, Randomized, Double-Blind study to Evaluate the Efficacy and Safety of XXX and XXX (Extended Release Tablet) Co-Administered in Patients with Type IIa or Type IIb Hyperlipidemia.

A Randomized, Comparative, Double-Blind, Parallel-Group, Multi-Center, Monotherapy Study of XXX in Patients with Newly Diagnosed Partial Seizures.

A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multi-Center Study of the Efficacy, Safety and Tolerability of Fixed Combination XXX Administered Orally, Once Daily for 6 months, compared to XXX alone or Placebo, in subjects with mixed Dyslipidemia Fredrickson Types IIa and IIb Study.

A 16-Week, Randomized, Double-Blind, Placebo and Pregabalin-Controlled, Multi-Center Trial of XXX in Patients with Post Herpetic Neuralgia (PHN).

A Phase 2, 8-week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Tolerability and Safety of XXX for Stress Urinary Incontinence in Women.

A Randomized, Double-Blind, Placebo-Controlled Trial to assess Safety and Tolerability during treatment of Type 2 Diabetes with Usual Diabetes Therapy and either CYCLOSET or Placebo.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of SGS742 in Subjects with Mild to Moderate Alzheimer's Disease.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patient with Mild to Moderate Alzheimer's Disease.

A Double-Blind, Placebo-Controlled, Multi-Center Study to assess the Safety and Efficacy of Dextromethorphan and Quinine at Two Dose Levels in the Treatment of the Pain of Diabetic Neuropathy.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of a Single, 1-hour Infusion of TS-001, in Acute Ischemic Stroke (AIS) Patients.

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety and Tolerability of Pioglitazone HCl (ACTOS) in combination with TAK-536 in subjects with Type 2 Diabetes.

SPONSORED RESEARCH (Continued): [2005 – 2007- Prior to Pivotal Research Centers]

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Lamotrigine 200-400 mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy of Safety of XXX in Subjects with Mild to Moderate Alzheimer's Disease.

A 24 week Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Safety, Tolerability and Efficacy of the Human Anti-IL-12 Antibody XXX in Subjects with Multiple Sclerosis with a 24-week Double-Blind Active Extension Phase.

Case Controlled DNA/RNA/SERUM/PLASMA/URINE Banking Study in Caucasians with Multiple Sclerosis.

An Open-Label, Randomized, Crossover Trial to assess Subject Preference for XXX compared to Conventional Baclofen Tablets in Subjects with Stable Multiple Sclerosis.

Trial to Reduce Cardiovascular Events with Aranesp Therapy - TREAT

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety and Tolerability of Pioglitazone HCl (Actos) in Combination with XXX in Subjects with Type 2 Diabetics.

Phase III Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of XXXXX Vaccine in Adult Patients Undergoing Cardiovascular Surgery.

A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of XXXXX Vaccine in Adult Patients Undergoing Cardiovascular Surgery.

EPIC (Effect of PhosLo on Parathyroid Hormone in Chronic Kidney Disease): A Prospective, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm, Comparison study of Calcium Acetate (PhosLo) on Parathyroid Hormone Levels in Subjects with Chronic Kidney Disease.

Comparative, Randomized, Single-dose 2-way crossover Bioavailability study of Sidmark Laboratories and Abbott Laboratories (Rythmol) 300 mg, PropafenoneHCl tablets in healthy adult males under fasting conditions.

Open-Label, Cross-Over study of the Pharmacokinetics of Asacol (2x400mg) Tablets vs. Colazai (3x750mg) Capsules in healthy male and female volunteers.

Comparison of the Pharmacokinetics and Pharmacodynamics of Omeprazole and Prilosec administered to healthy subjects with a between dose interval of 6 hours.

Phase 2 dose response assessment of the Safety and Immunogenicity of Transcutaneous Immunization using LT plus Tetanus Toxoid or LT alone.

A 3-way crossover pilot study to compare the Single dose Pharmacokinetics of two marketed Clarithromycin 500mg tablets and XXXXX.

The effects of Steady-State Ketoconazole on the Pharmacokinetics of Dexloxiglumide in healthy young subjects.

A Three-period crossover study evaluating XXXXX, XXXXX and a combination of both in a safety study.

SPONSORED RESEARCH (Continued): [2005 – 2007- Prior to Pivotal Research Centers]

A Long-term, Open-label, Rollover trial assessing the Safety and Tolerability of combination Tipranavir and Ritonavir use in HIV-1 infected subjects.

A Phase II Randomized, Placebo-Controlled, Double-Blinded study of XXX, a humanized monoclonal antibody that binds to the CD2 receptor, administered by subcutaneous injection to adults with Plaque Psoriasis.

A single center, Open-label, Dose-escalating, Pharmacokinetics study comparing the Pharmacokinetic profiles of BEMA Sumatriptan Formulations (AL-3813.03, AL-33813.02, AL-3813.04, AL-3803.01) to a referenced Sumatriptan subcutaneous injection in healthy older volunteers.

Pharmacokinetic study to assess the effect of Food and the bioavailability of a 200mg XXX tablet.

A randomized, double-blinded, placebo-controlled study evaluating the effect of XXXXX on Electroencephalographic (EEG) measurements in healthy older volunteers.

Open-label, Crossover, Single-dose study in healthy subjects to evaluate Pharmacokinetics and Tolerability of two Ziprasidone Hydrochloride Sustained Release Swellable-core tablet formulations under fasting conditions compared to GEODON commercial capsule.

An 8-week, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center study of XXX administered once daily in patients with Fibromyalgia.